Ortoma presents breakthrough 3D concept for orthopedic surgery at AAHKS Annual Meeting in Dallas
Ortoma AB (publ) ("Ortoma" or the "Company") announces today that the Company has initiated development in a new potential business area for the conversion of 2D x-ray images into 3D models based on the Company's unique AI platform. The concept will be unveiled in conjunction with the American Association of Hip and Knee Surgeons ("AAHKS") Annual Meeting in Dallas, USA later this week from 4 to 5 November, 2022.
Ortoma has demonstrated a “proof of concept” solution for converting 2D x-ray images into 3D models based on the Company's unique AI-based preoperative planning platform. This proof of concept work was initiated when the Company identified a strong need in the market which Ortoma has the unique capability to address. As Ortoma has already developed an advanced machine learning platform, the Company saw an additional opportunity to convert x-ray images into 3D models. The current technology for producing 3D models of, for example, knees and hips is done using a CT scan. While not all hospitals are equipped with a CT scan, conventional X-rays are usually available. Ortoma’s differentiated proof of concept solution will be demonstrated in association with the AAHKS knee and hip congress in Dallas, USA.
Linus Byström, CEO of Ortoma, comments:
"We see incredible market potential in converting x-ray imaging into 3D models. This is something that many in the industry have been unsuccessfully trying to achieve for many years and have yet to find a viable solution. Coming from a machine learning background and having lots of CT data, we can train the system to create models based on x-ray images that come close to matching 3D performance. Our solution has the potential to streamline care by shortening treatment times and generating significant cost savings for each patient and for healthcare systems globally. Developing this capability could result in a major business opportunity for Ortoma. We now look forward to presenting this to key industry players in conjunction with AAHKS in Dallas. Based on current activities, we see the potential to launch the first product, based on this technology, in 2024. I look forward to updating shareholders on the response from the market."
Ortoma – Improved Performance
For further information please contact:
Ortomas CEO Linus Byström
e-mail: info@ortoma.com
About Ortoma AB (publ)
Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The
purpose of the company’s surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure
and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the
patient. Ortoma’s surgical system is aimed at providing better patient outcomes, fewer complications and less follow‐up
surgeries – and thus better long‐term survival rates for implants. OTS is a system that is easily integrated into the processes
and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures
are performed each year where OTS could be used in hip, knee and spinal surgery. In Sweden, around 42,000 surgical
procedures were performed last year, involving hip, knee or spinal surgery. Ortoma’s B shares are listed on Spotlight Stock
Market.